Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Capital Expenditures (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Capital Expenditures for 4 consecutive years, with -$139000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to -$139000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $848000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $848000.0 for FY2025, 450.65% up from the prior year.
  • Capital Expenditures for Q4 2025 was -$139000.0 at Century Therapeutics, down from $195000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $24.0 million in Q3 2022, with the low at -$3.5 million in Q2 2022.
  • Average Capital Expenditures over 4 years is $3.3 million, with a median of $757000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures soared 344.5% in 2023, then tumbled 96.89% in 2024.
  • Over 4 years, Capital Expenditures stood at $6.3 million in 2022, then plummeted by 84.37% to $980000.0 in 2023, then crashed by 72.96% to $265000.0 in 2024, then crashed by 152.45% to -$139000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$139000.0, $195000.0, and $317000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.